Can real world data talk to the money?
This article was originally published in Scrip
Executive Summary
Over the past couple of years, real-world data (RWD) and real-world evidence (RWE) have emerged as key buzzwords along with big data, and we are set to hear even more of them, according to Richard Barker, director of the Centre for the Advancement of Sustainable Medical Innovation. Real-world studies (RWSs) are now becoming more common, but examples of their use and influence on reimbursement decisions or guidelines remain few and far between. Nevertheless, with their ability to demonstrate that a new intervention does work, after randomized controlled trials (RCTs) have shown that it can work, their use is growing, albeit in a fragmented and disconnected manner. These issues, along with other challenges relating to the use of RWD, were discussed at the eyeforpharma Real World Data Europe conference in London on 28–29 April 2014.
You may also be interested in...
Aetna: Entresto’s Label Enabled Outcome-Based Risk Share
Including the impact on hospitalizations in the label for Novartis's heart failure drug Entresto was critical to enable execution of outcome-based agreements. Such deals present an opportunity for pharma and payers to work together, but many challenges remain.
ISPOR Europe 2015: Are Spain And US The Ones To Watch For MEAs?
Despite the challenges with the implementation of managed entry agreements, the debate involving these complex market access routes is not abating. Speakers at the International Society for Pharmacoeconomics and Outcomes Research Europe meeting in Milan on 7–11 November 2015 discussed current experiences with such agreements across Europe, as they are about to make a bigger showing across the Atlantic.
Honing market access tactics given German drug assessment/price trends
Four years after its introduction, Germany's early benefit assessment process continues to make waves in the industry.